Drug Prices
Also in this weekly roundup of health news: AHA president and CEO Rick Pollack speaks to HealthLeaders about the association’s year ahead; digital health startups growing presence at this year’s Consumer Electronics Show; how consumers are and aren’t using popular health apps; and some Medicaid…
As Congress prioritizes action to lower drug prices, the Campaign for Sustainable Rx Pricing yesterday announced a website to help lawmakers and their staff better understand the crisis and bipartisan, market-based solutions.
AHA commends the Centers for Medicare & Medicaid Services' willingness to address excessive growth in drug prices, but urges CMS to consider narrowing the scope of the program.
AHA comments on the Centers for Medicare & Medicaid Services’ advance notice of proposed rulemaking on the International Pricing Index model for Medicare Part B drugs.
As urged by the AHA, the Health Resources and Services Administration today announced that it expects to publish online by April 1 drug ceiling prices under the 340B Drug Pricing Program.
The Campaign for Sustainable Rx Pricing, of which the AHA is a founding member, yesterday released a new ad urging Congress to keep its commitment to lower drug prices.
Special Bulletin on CMS’s Nov. 26 proposed rule aimed at lowering drug prices for beneficiaries enrolled in Medicare Advantage and Part D programs.
The Centers for Medicare & Medicaid Services late today issued a proposed rule that would provide Medicare Advantage and Part D plans more tools to negotiate lower drug prices.
The AHA today urged the Health Resources and Services Administration to meet the Jan. 1 effective date it has proposed for its final rule on drug ceiling prices and civil monetary penalties for manufacturers under the 340B Drug Pricing Program.
The AHA urges the Health Resources and Services Administration to meet the Jan. 1 effective date it has proposed for its final rule on drug ceiling prices and civil monetary penalties for manufacturers under the 340B Drug Pricing Program.